Edwards Lifesciences Unfavorable contract liability decreased by 16.2% to $22.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.6%, from $46.20M to $22.80M.
other_disposal_group_including_discontinued_operations_u_53ffa2| Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $66.00M | $53.70M | $46.20M | $36.80M | $33.20M | $27.20M | $22.80M |
| QoQ Change | — | — | -18.6% | -14.0% | -20.3% | -9.8% | -18.1% | -16.2% |
| YoY Change | — | — | — | — | — | -49.7% | -49.3% | -50.6% |